Two separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

Retatrutide + tirzepatide

Retatrutide + Tirzepatide

Retatrutide + tirzepatide: ingredient studies, complete-combination evidence gaps, dose, route and safety questions in the available research.

Peptide stack
Primary investigators

Recorded source check: 4 October 2026

Review and updates

Overview

This guide covers Retatrutide + Tirzepatide as a proposed combination. No primary study record of the complete combination is currently attached to this page, so the material here cannot establish an added benefit, a validated combined regimen, or a reliable rate of adverse events. Ingredient studies remain useful background, but they answer narrower questions about the intervention each paper actually tested. The gap described here concerns this guide’s linked sources and is not a claim that the combination has never been studied elsewhere.

Ingredients

  • RetatrutideRead the ingredient evidence and its limits.
  • TirzepatideRead the ingredient evidence and its limits.

The combination examined on this page contains Retatrutide + Tirzepatide. Each ingredient needs to be identified by its actual molecule and preparation before research can be matched to the combination. The linked ingredient guides provide a route into that evidence, while ingredients without a dedicated guide remain named explicitly. A shared nickname, similar product label, or premixed presentation cannot establish that every ingredient, concentration, and route matches a published intervention.

Why combine them?

The reason to investigate Retatrutide + Tirzepatide together must be separated from evidence that the combination improves an outcome. A plausible role for each ingredient can motivate a study, but it does not show whether their effects complement one another, overlap, or introduce additional problems. The sources attached to this guide do not resolve that comparison for the complete stack. A convincing test would compare the proposed combination with the relevant individual ingredients and measure both the intended benefit and adverse events.

Combination benefits

No effectiveness assessment for the complete Retatrutide + Tirzepatide combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Safety & interactions

This page does not establish the safety or interaction profile of Retatrutide + Tirzepatide taken together. Assessing that question requires the full formulation, route, exposure, concurrent treatments, and adverse-event reporting from relevant combination research. Tolerability observed with an ingredient alone cannot establish the safety of adding the other ingredients, and missing reports cannot be treated as reassurance. Any proposed clinical use also requires an assessment of the individual’s circumstances rather than a conclusion drawn solely from a stack name.

Read the Medical Disclaimer.

Forms & dosing

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete Retatrutide + Tirzepatide combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Complete-combination evidence has not yet been assessed for this guide.

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

IngredientPDF recordUnleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence
IngredientPDF recordRetatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models
IngredientPDF recordDetection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis
IngredientPDF recordContractile effects of retatrutide in isolated mouse atrial preparations
IngredientPDF recordThe Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity
IngredientPDF recordComparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice
IngredientPDF recordPerceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial
IngredientPDF recordDifferentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943
IngredientPDF recordEfficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison
IngredientPDF recordStructural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
IngredientPDF recordTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
IngredientPDF recordIncretin triple agonist retatrutide (LY3437943) alleviates obesityassociated cancer progression
IngredientPDF recordRationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
IngredientPDF recordDecreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids
IngredientPDF recordAssociation between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, doubleblind trial comparing retatrutide and placebo in people with obesity or overweight
IngredientPDF recordAppetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study
IngredientPDF recordMulti-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair
IngredientPDF recordOnline-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis
IngredientPDF recordA Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide
IngredientPDF recordA Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes
IngredientPDF recordA phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
IngredientPDF recordApitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
IngredientPDF recordAssociation between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study
IngredientPDF recordAssociation of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial
IngredientPDF recordAssociation of tirzepatide with changes in OSA‑related measures based on baseline characteristics – post hoc analyses of SURMOUNT‑OSA
IngredientPDF recordBody composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight
IngredientPDF recordChange in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy
IngredientPDF recordCounterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide
IngredientPDF recordEarly Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
IngredientPDF recordEffect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study
IngredientPDF recordEffect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity
IngredientPDF recordEffects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
IngredientPDF recordEffects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
IngredientPDF recordEfficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial
IngredientPDF recordEfficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS-AP-combo and SURPASS-3
IngredientPDF recordEfficacy and tolerability of tirzepatide, a dual glucosedependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens
IngredientPDF recordGastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials
IngredientPDF recordIxekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
IngredientPDF recordLong-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4
IngredientPDF recordPeople With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment
IngredientPDF recordRelationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction–Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide
IngredientPDF recordSafety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS- SWITCH
IngredientPDF recordShifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1
IngredientPDF recordThe dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
IngredientPDF recordTime to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials
IngredientPDF recordTirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials
IngredientPDF recordTirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials
IngredientPDF recordTirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial
IngredientPDF recordTirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
IngredientPDF recordTirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial
IngredientPDF recordTirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight
IngredientPDF recordTirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
IngredientPDF recordTirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial
IngredientPDF recordTirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
IngredientPDF recordTirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
IngredientPDF recordWeight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1
IngredientPDF recordEffects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
IngredientPDF recordTirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
IngredientPDF recordTirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
IngredientPDF recordTirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial
IngredientPDF recordTirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial
IngredientPDF recordPredictors of Initial and Sustained Glycemic and Weight Response to Tirzepatide: A Post Hoc Analysis of SURPASS-4
IngredientPDF recordTirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
IngredientPDF recordEarly-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program
IngredientPDF recordEstimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND

FAQs

Do the ingredient studies prove that the complete stack works?
Quick answer:

No effectiveness assessment for the complete Retatrutide + Tirzepatide combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Can separate study doses be combined into a stack protocol?
Quick answer:

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete Retatrutide + Tirzepatide combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for Retatrutide + tirzepatide.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

0 sources

This page does not yet have an assessed reference supporting a clinical conclusion about the complete topic. Ingredient links and the broader source library can help locate relevant research, but a related paper is not automatically evidence for the intervention named here. Any future citation needs to be matched to its actual population, formulation, comparison, and outcome. The absence of a reference on this page describes the present review and should not be interpreted as a literature-wide absence of research.